Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii

Mycoses

Volumn 55, Issue 2, 2012, Pages 156-160

  Saribas, Zeynep ^a   Yurdakul, Pinar ^a   Cetin Hazirolan, Gulsen ^a   Arikan Akdagli, Sevtap ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Candida guilliermondii; Candida parapsilosis; Echinocandins; In vitro susceptibility testing

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA PARAPSILOSIS; FUNGUS ISOLATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; SERUM;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; BLOOD PROTEINS; CANDIDA; CANDIDIASIS, INVASIVE; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; SERUM;

ASPERGILLUS; CANDIDA; CANDIDA PARAPSILOSIS; PICHIA GUILLIERMONDII;

EID: 84857237557     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02050.x     Document Type: Article

References (20)

1. Cheung C, Guo Y, Gialanella P, Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection 2006; 34: 345-8.
2. Colombo AL, Ngai AL, Bourque M et al. Caspofungin use in patients with invasive candidiasis caused by common non-albicans species: review of the caspofungin database. Antimicrob Agents Chemother 2010; 54: 1864-71.
3. Kanafani ZA, Perfect JR. Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008; 46: 120-8.
4. Rogers TR, Frost S. Newer antifungal agents for invasive fungal infections in patients with haematological malignancy. Br J Haematol 2008; 144: 629-41.
5. Torre P, Meyer DK, Reboli AC. Anidulafungin: a novel echinocandin for Candida infections. Future Microbiol 2008; 3: 593-601.
6. Kauffman CA, Carver PL. Update on echinocandin antifungals. Semin Respir Crit Care Med 2008; 29: 211-9.
7. Paderu P, Garcia-Effron G, Balashov S et al. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007; 51: 2253-6.
8. Odabasi ZV, Paetznick V, Rex JH, Ostrosky-Zeichner L. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother 2007; 51: 4214-6.
9. Wiederhold NP, Najvar LK, Bocanegra R et al. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 2007; 51: 1616-20.
10. Inskeep P, Lin J. Plasma protein binding of anidulafungin is similar to other major echinocandins. 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain 2008; no. P-1048
11. Larone DH. Medically Important Fungi. A Guide to Identification, 2nd edn. Washington, DC: American Society for Microbiology, 1993: 57-61.
12. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard, Third edn. CLSI Document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
13. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Third Informational Supplement. CLSI Document M27-S3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
14. Pfaller MA, Diekema DJ, Andes D et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011. doi:
15. Pfaller MA, Boyken L, Hollis RJ et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 2010; 48: 52-56.
16. Pfaller MA, Boyken L, Hollins RJ et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150-6.
17. Canton E, Peman J, Sastre M, Romero M, Espinel-Ingroff A. Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. Antimicrob Agents Chemother 2006; 50: 2829-32.
18. Ishikawa J, Meada T, Matsumura I et al. Antifungal activity of micafungin in serum. Antimicrob Agents Chemother 2009; 53: 4559-62.
19. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008; 46: 2620-9.
20. Arendrup MC, Garcia-Effron G, Lass-Flörl C et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution with RPMI and Isosensitest media. Antimicrob Agents Chemother 2010; 54: 426-39.